Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $4.96.
HUMA has been the subject of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research note on Friday, October 2nd. Williams Trading set a $1.00 price target on Humacyte in a research note on Friday, October 16th. Benchmark cut their price target on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a report on Thursday, August 13th. Wall Street Zen cut Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reissued a “buy” rating on shares of Humacyte in a research note on Friday, October 16th.
Check Out Our Latest Stock Report on HUMA
Humacyte Stock Up 11.4%
Shares of NASDAQ:HUMA opened at $0.45 on Friday. Humacyte has a 12-month low of $0.34 and a 12-month high of $1.78. The business has a fifty day simple moving average of $0.54 and a 200 day simple moving average of $0.82.
Humacyte (NASDAQ:HUMA – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. On average, analysts forecast that Humacyte will post -0.40 EPS for the current fiscal year.
Hedge Funds Weigh In On Humacyte
A number of large investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Humacyte during the 2nd quarter valued at $3,777,000. Alyeska Investment Group L.P. acquired a new position in Humacyte during the second quarter worth $4,700,000. GSA Capital Partners LLP bought a new position in shares of Humacyte in the second quarter valued at $785,000. Beacon Pointe Advisors LLC bought a new position in shares of Humacyte in the second quarter valued at $28,000. Finally, Bank of America Corp DE bought a new position in shares of Humacyte in the second quarter valued at $451,000. 44.71% of the stock is currently owned by institutional investors.
About Humacyte
Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.
Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.
See Also
- Five stocks we like better than Humacyte
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
